Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Pacritinib

33ee877c-8288-5fa0-85e5-4e44347f96c6 · FDA Approved · targets JAK2

Pacritinib

MeasuredReference

Pacritinib targets IRAK1, TNIK, CLK1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

IRAK1TNIKCLK1TYK2JAK2

Top hallmarks

  • tumor promoting inflammation9.4k
  • proliferation7.3k
  • evading apoptosis7.3k

Top pathways disrupted

  • pi3k akt mtor signaling15.4k
  • apical junction14.9k
  • allograft rejection14.4k

Resistance landscape — Pacritinib

MeasuredReference

1 known oncogenic variants exist on Pacritinib's top targets — see detail for inhibition impact.

Open in new tab